This is incorrect and one of the roots of you error.
So I shouldn't conclude that it is likely, based on available information now, that the median control PFS in this trial is high, relative to past (limited) experience for RFA for HCC with larger tumors?
That it is just as likely that either:
- The trial was continued due to some other reason, or
- Celsion management lied about enrollment statistics, or
- Arithmetic is inherently unreliable?
You yourself have drawn pretty specific conclusions about the performance of the control arm in the ONTY start trial based on your own modeling using publicly available information. Why the confidence in that case, and the insistence that we know nothing in any other case?
Market Data 
Markets 
AI
